Andrx adds business development VP
Jeffrey Long-McGie joins Andrx in the new post of VP-business development; he is a former specialty pharma analyst with ThinkEquity Partners. Andrx Pharma VP Habib Nasirullah will assume responsibility for international business development; Nasirullah joined Andrx in 2002 and has overseen product commercialization and engineering projects...
You may also be interested in...
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.